Treatment of chronic myeloid leukemia in blast crisis

被引：33

作者：

Hehlmann, R. ^{[1
]}

Saussele, S. ^{[1
]}

机构：

[1] Heidelberg Univ, Med Fak Mannheim, D-6800 Mannheim, Germany

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷 / 12期

关键词：

D O I：

10.3324/haematol.2008.001214

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1765 / 1769

页数：5

共 34 条

[1] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[2] The biology of CML blast crisis [J].

Calabretta, B ;

Perrotti, D .

BLOOD, 2004, 103 (11) :4010-4022

[3] A STUDY OF PROGNOSTIC FACTORS IN BLAST CRISIS OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA [J].

CERVANTES, F ;

ROZMAN, M ;

ROSELL, J ;

URBANOISPIZUA, A ;

MONTSERRAT, E ;

ROZMAN, C .

BRITISH JOURNAL OF HAEMATOLOGY, 1990, 76 (01) :27-32

[4]

CORTES J, 2008, LEUKEMIA 0828

[5] Staging of chronic myeloid leukemia in the imatinib era - An evaluation of the World Health Organization proposal [J].

Cortes, JE ;

Talpaz, M ;

O'Brien, S ;

Faderl, S ;

Garcia-Manero, G ;

Ferrajoli, A ;

Verstovsek, S ;

Rios, MB ;

Shan, J ;

Kantarjian, HM .

CANCER, 2006, 106 (06) :1306-1315

[6] Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib [J].

Cortes, Jorge ;

Jabbour, Elias ;

Daley, George Q. ;

O'Brien, Susan ;

Verstovsek, Srdan ;

Koller, Charles ;

Zhu, Yali ;

Statkevich, Paul ;

Kantarjian, Hagop .

CANCER, 2007, 110 (06) :1295-1302

[7]

Deininger M, 2006, HAEMATOLOGICA, V91, P452

[8] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[9] Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis [J].

Fruehauf, Stefan ;

Topaly, Julian ;

Buss, Eike C. ;

Fischer, Thomas ;

Offmann, Oliver G. ;

Emmerich, Bertold ;

Muller, Martin C. ;

Schuld, Peter ;

Balleisen, Leopold ;

Hehlmann, Rbdiger ;

Ho, Anthony D. ;

Hochhaus, Andreas .

CANCER, 2007, 109 (08) :1543-1549

[10] Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program [J].

Ganibacoiti, Carlo ;

CorteS, Jorge ;

Kim, Dong-Wook ;

Dombret, Herve ;

Zhu, Chao ;

Van Tornout, Jan M. A. ;

Garzon, Felix T. ;

Baccarani, Michele .

BLOOD, 2007, 110 (11) :145A-145A

← 1 2 3 4 →